Findings from a phase 2 trial published in JTO Clinical and Research Reports suggest that pembrolizumab (Keytruda) plus ...

For nearly 20 years, mesothelioma treatment options were limited to a single regimen: pemetrexed with a platinum agent. Now, ...

The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC ...

A lifesaving medication has been urgently recalled and demanded to be under quarantine by the UK government due to results found during testing ...

It is expected that a total of 420 patients will be randomized 1:1 to receive either of the following dosing combinations as follows: Ivonescimab + chemotherapy [Pemetrexed + Carboplatin] Placebo ...

Chemotherapy remains part of the standard of care in many tumor types, leading Summit to include drugs such as carboplatin and pemetrexed in its phase 3 treatment regimens. Yet, ADC developers see ...

Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] Draft guidance Technology appraisal guidance 2 April ...